Hypothesis

Transient senescent cells act as network chaperones that buffer proteotoxic stress through EZH2‑SIRT1‑dependent chromatin remodeling and secretion of extracellular chaperones; their removal by senolytics destabilizes this buffering capacity, leading to increased protein aggregation and tissue dysfunction.

Mechanistic Basis

• Senescent fibroblasts and epithelial cells up‑regulate the histone methyltransferase EZH2 and the deacetylase SIRT1 [2,3]. This rewires protein‑protein interaction networks to reinforce DNA‑damage response hubs and to repress transcription of genes encoding aggregation‑prone proteins (e.g., mutant SOD1, HTT exon1) via H3K27me3 deposition.

• The senescence‑associated secretory phenotype (SASP) includes soluble chaperones such as clusterin and extracellular HSP70 that can bind misfolded proteins in the microenvironment, reducing nucleation of toxic aggregates [4].

• In young tissue, senescent cells are cleared promptly by immune surveillance, allowing the chaperone hub to act only during the window of damage response [5]. When clearance fails with age, the same hub becomes chronically active, shifting from protection to maladaptive inflammation.

Testable Predictions

1. Acute senolytic treatment (e.g., navitoclax + dasatinib) in young mice will increase the insoluble protein fraction in liver and pancreas within 48 h, measured by SDS‑resistant Western blot for ubiquitin‑conjugated species.

2. Co‑culture of senescent hepatocytes with primary hepatocytes expressing an aggregation‑prone reporter (e.g., PolyQ‑GFP) will decrease reporter aggregation; this protective effect will be lost upon EZH2 inhibition (GSK126) or senolytic removal of the senescent partners.

3. Overexpression of EZH2 or SIRT1 in senescent cells prior to senolytic exposure will rescue the proteostasis defect, restoring normal levels of soluble versus insoluble protein pools.

Experimental Approach

• In vivo: Treat 3‑month‑old C57BL/6J mice with a single dose of navitoclax (10 mg/kg) plus dasatinib (5 mg/kg). Harvest liver and pancreas at 0, 24, 48 h. Perform fractionation to separate soluble and insoluble protein pools, immunoblot for ubiquitin, p62, and specific aggregation‑prone substrates (mutant SOD1^G93A, HTT‑Q97). Compare to vehicle controls.

• In vitro: Isolate senescent fibroblasts via irradiation (10 Gy) and confirm p16^INK4a^ and SA‑β‑gal positivity. Co‑culture with HEK293 cells expressing mCherry‑HTT‑Q74. Treat half of the cultures with senolytic (ABT‑263) or EZH2 inhibitor. Quantify mCherry puncta per cell by high‑content imaging.

• Rescue: Transduce senescent cells with EZH2‑WT or SIRT1‑WT lentivirus before senolytic exposure; assess whether aggregation in co‑culture partners is prevented.

Potential Outcomes and Interpretation

• If senolysis elevates insoluble protein aggregates and this is prevented by EZH2/SIRT1 overexpression, the data support the hypothesis that senescent cells act as transient chaperone hubs that maintain proteostasis via chromatin‑mediated repression and extracellular chaperone secretion.
• If no change in aggregation is observed, the chaperone model would be refuted, suggesting that senescent cell removal does not disturb core proteostasis networks under these conditions.
• A tissue‑specific effect (strong in pancreas/liver, weak in muscle) would indicate that the chaperone function is most critical in secretory‑organ environments where misfolded load is high.

Broader Implications

This framework refines the senolytic paradigm: rather than indiscriminate clearance, timing and context matter. Preserving the transient chaperone activity of senescent cells—or pharmacologically mimicking their EZH2/SIRT1‑driven proteostatic network—could allow removal of the harmful SASP while retaining the quality‑control benefit. Future screens might target upstream regulators of EZH2 in senescent cells to uncouple the chaperone role from chronic inflammation.